Research institution
ANRS, Emerging Infectious Diseases Clinical Trials
Studies where ANRS, Emerging Infectious Diseases is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 31HIV Infection
HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM)
The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution.
- Trial name
- OBSOCAM (NCT06913959)
- Testing
- Prospective
- Volunteers
- 220 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection
Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption
Natural HIV controllers (HICs) and post-treatment controllers (PTCs) are rare examples of people living with HIV (PLWH) who achieve control of HIV replication without the need for antiretroviral therapy (ART).
- Trial name
- NCT07081763
- Testing
- Baricitinib 2 MG, Sirolimus 2 MG
- Volunteers
- 191 people
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, Immunodeficiency
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the…
- Trial name
- OPTICOV (NCT05587894)
- Testing
- Paxlovid 5 days, Paxlovid 10 days, Veklury
- Where
- 18 sites in France, Italy and 1 more
- Volunteers
- 256 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HBV Infection, Pregnancy
"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"
To achieve global elimination of hepatitis B virus (HBV), it is crucial to eliminate HBV mother-to-child transmission (MTCT) by ensuring high coverage of birth dose vaccine and expanding the adoption of peripartum antiviral…
- Trial name
- HIPOCAMP (NCT07054359)
- Testing
- HBsAg RDT Women, Treatment by TDF if HBcrAg RDT positive, Treatment by TDF
- Where
- Vietnam
- Volunteers
- 3,200 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Older Adults
Frailty, Geriatric Syndromes and Care Pathways of Older Adults Living With HIV in West Africa
With currently available antiretroviral therapy, people living with HIV (PLWHIV) are living longer. This exposure to HIV and combination antiretroviral therapy may accelerate the aging of this population, thus increasing the…
- Trial name
- NCT07355413
- Where
- 6 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV - Human Immunodeficiency Virus
Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy
The purpose of this trial is to evaluate the immunomodulatory effects of glatiramer acetate (GA) in improving the recovery of CD4 T cells and the CD4/CD8 ratio in people living with HIV (PLWHIV) who have poor immune recovery and…
- Trial name
- GEODE (NCT07851337)
- Testing
- - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml
- Volunteers
- 36 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV/AIDS
Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.
The purpose of this study is to evaluate the efficacy, acceptability, and safety of a simplified event-driven pre-exposure prophylaxis of HIV based on oral TAF/FTC in HIV-uninfected cisgender men who have sex with men (MSM).
- Trial name
- SimpPrEP (NCT05813964)
- Testing
- TDF/FTC 300mg/200mg fixed-dose combination tablets, TAF/FTC 25mg/200mg fixed-dose combination tablets
- Where
- 6 sites in France, Thailand
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Detection of Specific Metabolic Signatures by Nuclear Magnetic Resonance or Metabolomic NMR in Correlation With Markers of Inflammation or Immune Activation and the Risk of Developing Neurocognitive Disorders - Longitudinal Retrospective Study Nested in the ANRS12225 PEDIACAM III Cohort
The ANRS12225 PEDIACAM III cohort involves a cohort of young adolescents living with HIV placed early (median: 4 months) on antiretroviral therapy (ART) and living without HIV monitored in Cameroon.
- Trial name
- ANRS0213sMIND (NCT07770568)
- Volunteers
- 128 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.
- Trial name
- ELDORADO (NCT06203132)
- Testing
- Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine
- Where
- 19 sites in Brazil, Cameroon and 4 more
- Volunteers
- 610 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculous Meningitis
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults…
- Trial name
- INTENSE-TBM (NCT04145258)
- Testing
- Aspirin, WHO TBM treatment, Intensified TBM treatment
- Where
- 13 sites in Côte d’Ivoire, Madagascar and 2 more
- Volunteers
- 768 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Completed, with results posted
All 5HIV Infection
Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
The development of a safe and effective HIV-1 vaccine strategy would probably be the best solution for the ultimate control of the worldwide AIDS pandemic.
- Trial name
- VRI01 (NCT02038842)
- Testing
- LIPO-5, MVA HIV-B (MVATG17401), GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
This multicenter, international, non randomized (single arm), open, phase II trial aims to evaluate the capacity of the dual combination raltegravir/etravirine to maintain virological success in virologically suppressed HIV-1…
- Trial name
- NCT02212379
- Testing
- raltegravir and etravirine
- Where
- 19 sites in France, Spain
- Volunteers
- 170 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-2 Infection
Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
The HIV-2 is less common ie 1-2 million people in West Africa. HIV-2 does have the same sensitivity to antiretroviral treatment (ART) compared to HIV-1.
- Trial name
- VIH-2 (NCT01605890)
- Testing
- emtricitabine / tenofovir disoproxil fumarate / raltegravir .
- Where
- France
- Volunteers
- 30 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Hepatitis Virus
Feasibility of Interventions on People Who Inject Drugs in Vietnam
This study aims at assessing the feasibility of implementing an interventional cohort of people who inject drugs in Haiphong, Viet Nam.
- Conditions
- HIV, Hepatitis Virus, Substance Abuse
- Trial name
- DRIVE-IN (NCT02573948)
- Testing
- no intervention is assessed
- Where
- Vietnam
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, HIV Infections
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Since the first line antiretroviral (ARV) treatment is now largely accessible in the Sub-Saharian Africa countries, documentation of virological failure, drug resistance patterns and second line treatment evaluation are still to…
- Trial name
- 2LADY (NCT00928187)
- Testing
- emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line), abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line), emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
- Where
- 3 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 454 people
- Sponsor
- ANRS, Emerging Infectious Diseases